

PUBLICATIONS

1) Pradella D, Deflorian G, Pezzotta A, Di Matteo A, Belloni E, Campolungo D, Paradisi A, Bugatti M, Vermi W, Campioni M, Chiapparino A, Scietti L, Forneris F, Giampietro C, Volf N, Rehman M, Zacchigna S, Paronetto MP, Pistocchi A, Eichmann A, Mehlen P, **Ghigna C**. A ligand-insensitive UNC5B splicing isoform regulates angiogenesis by promoting apoptosis. *Nat Commun*. 2021;12: 4872.

IF= 14.919

2) Oh J, Pradella D, Shao C, Li H, Liu Y, Choi N, Ha J, Ruggiero S, Zheng X, **Ghigna C**, Zheng X, Shen H. Widespread Alternative Splicing Changes in Metastatic Breast Cancer Cells. *Cells*. 2021; 10: 85. **§Corresponding author.**

IF= 6.6

3) Oh J, Pradell P, Kim Y, Shao C, Li H, Choi N, Ha J, Matteo A, Fu X, Xuexiu Zheng X, **Ghigna C**, Shen H. Global alternative splicing defects in human breast cancer cells. *Cancers*. 2021; 13: 3071. **§Corresponding author.**

IF= 6.639

4) Ha J, Jang H, Choi N, Oh J, Min C, Pradella D, Jung DW, Williams DR, Park D, **Ghigna C**, Zheng X, Shen H. SRSF9 Regulates Cassette Exon Splicing of Caspase-2 by Interacting with Its Downstream Exon. *Cells*. 2021; 10: 679.

IF= 6.6

5) Di Matteo A, Belloni E, Pradella D, Cappelletto A, Volf N, Zacchigna S, **Ghigna C**. Alternative splicing in endothelial cells: novel therapeutic opportunities in cancer angiogenesis. *J Exp Clin Cancer Res*. 2020; 39:275

IF= 11.161

6) Oh J, Liu Y, Choi N, Ha J, Pradella D, **Ghigna C**, Zheng X, Shen H. Opposite Roles of Tra2 β and SRSF9 in the v10 Exon Splicing of CD44. *Cancers* 2020; 12:3195

IF= 6.639

7) **Ghigna C**, Paronetto MP. Alternative Splicing: Recent Insights into Mechanisms and Functional Roles. *Cells* 2020; 9:2327.

IF= 6.6

8) Choi N, Liu Y, Oh J, Ha J, **Ghigna C**, Zheng X, Shen H. Relative strength of 5' splice-site strength defines functions of SRSF2 and SRSF6 in alternative splicing of Bcl-x pre-mRNA. *BMB Rep*. 2020:5137

IF= 4.778

9) Belloni E, Di Matteo A, Pradella D, Vacca M, Wyatt CDR, Alfieri R, Maffia A, Sabbioneda S, **Ghigna C**. Gene Expression Profiles Controlled by the Alternative Splicing Factor Nova2 in Endothelial Cells. *Cells* 2019; 8:1498

IF= 6.6

10) Biamonti G, Amato A, Belloni E, Di Matteo A, Infantino L, Pradella D, **Ghigna C**. Alternative splicing in Alzheimer's disease. *Aging Clin Exp Res*. 2019
IF= 3.636

11) Angiolini F, Belloni E, Giordano M, Campioni M, Forneris F, Paronetto MP, Lupia M, Brandas C, Pradella D, Di Matteo A, Giampietro C, Jodice G, Luise C, Bertalot G, Freddi S, Malinverno M, Irimia M, Moulton JD, Summerton J, Chiapparino A, Ghilardi C, Giavazzi R, Nyqvist D, Gabellini D, Dejana E, Cavallaro U, **Ghigna C**. A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. *eLife* 2019; 8:e44305
IF= 8.14

12) Nakka K, **Ghigna C**, Gabellini D, Dilworth FJ. Diversification of the muscle proteome through alternative splicing. *Skelet Muscle* 2018; 8:8
IF= 4.912

13) Pradella D, Naro C, Sette C, **Ghigna C**. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. *Molecular Cancer* 2017; 16:8
IF= 27.401

14) Giampietro C, Deflorian G, Gallo S, Di Matteo A, Pradella D, Bonomi S, Belloni E, Nyqvist D, Quaranta V, Confalonieri S, Bertalot G, Orsenigo F, Pisati F, Ferrero E, Biamonti G, Fredrickx E, Taveggia C, Wyatt CD, Irimia M, Di Fiore PP, Blencowe BJ, Dejana E, **Ghigna C**. The alternative splicing factor Nova2 regulates vascular development and lumen formation. *Nat Commun*. 2015; 6:8479.
IF= 14.919

15) **Ghigna C**, Cartegni L, Jordan P, Paronetto MP. Posttranscriptional Regulation and RNA Binding Proteins in Cancer Biology. *Biomed Res Int*. 2015; 2015:897821
IF= 3.411

16) Frisone P, Pradella D, Di Matteo A, Belloni E, **Ghigna C**, Paronetto MP. SAM68: signal transduction and RNA metabolism in human cancer. *Biomed Res Int*. 2015; 2015:528954
§Corresponding author
IF= 3.411

17) Loh TJ, Cho S, Moon H, Jang HN, Williams DR, Jung DW, Kim IC, **Ghigna C**, Biamonti G, Zheng X, Shen H. hnRNP L inhibits CD44 V10 exon splicing through interacting with its upstream intron. *Biochim Biophys Acta* 2015; 1849:743
IF= 4.490

18) Moon H, Cho S, Loh TJ, Oh HK, Jang HN, Zhou J, Kwon YS, Liao DJ, Jun Y, Eom S, **Ghigna C**, Biamonti G, Green MR, Zheng X, Shen H. SRSF2 promotes splicing and transcription of exon 11 included isoform in Ron proto-oncogene. *Biochim Biophys Acta* 2014; 1839:1132
IF= 4.490

19) Biamonti G, Catillo M, Pignataro D, Montecucco A, **Ghigna C**. The alternative splicing side of cancer. *Semin Cell Dev Biol* 2014; 32:30
IF= 7.727

20) Moon H, Cho S, Loh TJ, Zhou J, **Ghigna C**, Biamonti G, Green MR, Zheng X, Shen H. A 2-nt RNA enhancer on exon 11 promotes exon 11 inclusion of the Ron proto-oncogene. *Oncol Rep.* 2014; 31:450

IF= 5.075

21) Sette C, Ladomery M, **Ghigna C**. Alternative splicing: role in cancer development and progression. *Int J Cell Biol.* 2013; 2013:421606

22) Bonomi S, Gallo S, Catillo M, Pignataro D, Biamonti G, **Ghigna C**. Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy. *Int J Cell Biol.* 2013; 2013:962038

23) **Ghigna C**, Riva S, Biamonti G. Alternative splicing of tumor suppressors and oncogenes. *Cancer Treat Res.* 2013; 158:95

24) Siegfried Z, Bonomi S, **Ghigna C**, Karni R. Regulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in Cancer. *Int J Cell Biol.* 2013; 2013:568931

25) Bonomi S, di Matteo A, Buratti E, Cabianca DS, Baralle FE, **Ghigna C***, Biamonti G. HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition. *Nucleic Acids Res.* 2013; 41:8665 ***Corresponding author**

IF= 16.971

26) Biamonti G, Bonomi S, Gallo S, **Ghigna C**. Making alternative splicing decisions during epithelial-to-mesenchymal transition (EMT). *Cell Mol Life Sci.* 2012; 69:2515

IF= 9.261

27) Valacca C, Bonomi S, Buratti E, Pedrotti S, Baralle FE, Sette C, **Ghigna C***, Biamonti G. Sam68 regulates EMT through AS-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. *J Cell Biol.* 2010; 191:87. ***Co-last author**

IF= 10.539

28) **Ghigna C***, De Toledo M, Bonomi S, Valacca C, Gallo S, Apicella M, Eperon I, Tazi J, Biamonti G. Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives. *RNA Biol.* 2010; 7:495. ***Corresponding author**

IF= 4.652

29) Pistoni M, **Ghigna C**, Gabellini D. Alternative splicing and muscular dystrophy. *RNA Biol.* 2010; 7:441

IF= 4.652

30) **Ghigna C§**, Valacca C, Biamonti G. Alternative splicing and tumor progression. *Current Genomics* 2008; 9:556. **§Corresponding author**

IF= 2.236

31) Valgardsdottir R, Chiodi I, Giordano M, Rossi A, Bazzini S, **Ghigna C**, Riva S, Biamonti G. Transcription of SatelliteIII non-coding RNAs is a general stress response in human cells. *Nucleic Acids Res.* 2008; 36:423

IF= 16.971

32) **Ghigna C**, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, Green MR, Riva S, Biamonti G. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. *Molecular Cell* 2005; 20:881

IF= 17.970

33) Chiodi I, Corioni M, Giordano M, Valgardsdottir R, **Ghigna C**, Cobianchi F, Xu RM, Riva S, Biamonti G. RNA recognition motif 2 directs the recruitment of SF2/ASF to nuclear stress bodies. *Nucleic Acids Res.* 2004; 32:4127

IF= 16.971

34) Shen H, Kan JL, **Ghigna C**, Biamonti G, Green MR. A single polypyrimidine tract binding protein (PTB) binding site mediates splicing inhibition at mouse IgM exons M1 and M2. *RNA* 2004; 10:787

IF= 4.942

35) **Ghigna C**, Moroni M, Porta C, Riva S, Biamonti G. Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. *Cancer Res.* 1998; 58:5818

IF= 12.701

36) Biamonti G, **Ghigna C**, Caporali R, Montecucco C. Heterogeneous nuclear ribonucleoproteins (hnRNPs): an emerging family of autoantigens in rheumatic diseases. *Clin Exp Rheumatol.* 1998; 16:317

IF= 4.473

37) Camacho-Vanegas O, Weighardt F, **Ghigna C**, Amaldi F, Riva S, Biamonti G. Growth-dependent and growth-independent translation of messengers for heterogeneous nuclear ribonucleoproteins. *Nucleic Acids Res.* 1997; 25:3950

IF= 16.971